PTC Therapeutics Inc (NASDAQ: PTCT) kicked off on Tuesday, up 4.20% from the previous trading day, before settling in for the closing price of $45.93. Over the past 52 weeks, PTCT has traded in a range of $28.72-$58.38.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Annual sales at Healthcare sector company grew by 23.09% over the past five years. While this was happening, its average annual earnings per share was recorded 263.45%. With a float of $77.14 million, this company’s outstanding shares have now reached $79.23 million.
Let’s look at the performance matrix of the company that is accounted for 939 employees. In terms of profitability, gross margin is 96.52%, operating margin of 40.61%, and the pretax margin is 36.75%.
PTC Therapeutics Inc (PTCT) Insider and Institutional Ownership
Our next focus will be how large-scale investors are participating in this stock of the Biotechnology Industry. The insider ownership of PTC Therapeutics Inc is 2.67%, while institutional ownership is 98.36%. The most recent insider transaction that took place on May 15 ’25, was worth 89,081. In this transaction EXEC. VP AND CLO of this company sold 1,929 shares at a rate of $46.18, taking the stock ownership to the 103,901 shares. Before that another transaction happened on May 16 ’25, when Company’s EXEC. VP AND CLO sold 883 for $46.02, making the entire transaction worth $40,636. This insider now owns 103,901 shares in total.
PTC Therapeutics Inc (PTCT) Latest Financial update
Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.41 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 263.45% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 55.77% during the next five years compared to -2.04% drop over the previous five years of trading.
PTC Therapeutics Inc (NASDAQ: PTCT) Trading Performance Indicators
Take a look at PTC Therapeutics Inc’s (PTCT) current performance indicators. Last quarter, stock had a quick ratio of 3.85. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 2.14. Likewise, its price to free cash flow for the trailing twelve months is 5.47.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is 6.51, a number that is poised to hit -1.04 in the next quarter and is forecasted to reach -2.61 in one year’s time.
Technical Analysis of PTC Therapeutics Inc (PTCT)
PTC Therapeutics Inc (NASDAQ: PTCT) saw its 5-day average volume 0.88 million, a negative change from its year-to-date volume of 1.03 million. As of the previous 9 days, the stock’s Stochastic %D was 57.21%. Additionally, its Average True Range was 2.60.
During the past 100 days, PTC Therapeutics Inc’s (PTCT) raw stochastic average was set at 53.10%, which indicates a significant decrease from 88.73% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 55.00% in the past 14 days, which was lower than the 64.15% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $48.00, while its 200-day Moving Average is $43.92. Nevertheless, the first resistance level for the watch stands at $49.28 in the near term. At $50.71, the stock is likely to face the second major resistance level. The third major resistance level sits at $52.29. If the price goes on to break the first support level at $46.27, it is likely to go to the next support level at $44.69. The third support level lies at $43.27 if the price breaches the second support level.
PTC Therapeutics Inc (NASDAQ: PTCT) Key Stats
The company with the Market Capitalisation of 3.79 billion has total of 79,257K Shares Outstanding. Its annual sales at the moment are 806,780 K in contrast with the sum of -363,300 K annual income. Company’s last quarter sales were recorded 1,176 M and last quarter income was 866,560 K.
